-+ 0.00%
-+ 0.00%
-+ 0.00%

Fulcrum Therapeutics offers CEO cash retention payment of $370,040 tied to change in control

PUBT·06/11/2026 20:31:11
Listen to the news
Fulcrum Therapeutics offers CEO cash retention payment of $370,040 tied to change in control
  • Fulcrum Therapeutics set cash retention payments for nine remaining full-time employees tied to a Change in Control or qualifying termination.
  • CEO Alex C. Sapir: USD 370,040; CFO Alan Musso: USD 195,200; Chief Legal Officer Curtis Oltmans: USD 195,480.
  • Payments require completion of transitional duties, as determined by the board or CEO depending on the executive.
  • Employment agreements were amended June 5, 2026 for Sapir and Oltmans, June 11, 2026 for Musso.
  • Change in Control benefits were extended to remaining vice president-level staff and above if terminated other than for Cause within six months pre-transaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-267659), on June 11, 2026, and is solely responsible for the information contained therein.